FindMyKOL

Laurence Sperling, MD

Basic profile

Emory University

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionAtlanta, GA · SoutheastSpecialtyCardiovascular DiseaseFocusCardiology
Last active 2024EmergingFindMyKOL type: NationalLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Laurence Sperling is a Cardiology physician affiliated with Emory University. OpenAlex indexes 556 publications with 34,358 citations (h-index 69); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Cardiovascular Disease profiles in the FindMyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
556publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

34,358citations

Citations across these publications.

69h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Novartis
    Program year20251 paymentResearch
    $4,337
  • Regeneron
    Program year20251 paymentResearch
    $1,821
  • Boehringer Ingelheim Pharmaceuticals, Inc.
    Program year20221 payment
    $50
All 4 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    87.8%
    Statin25.1%
    Atorvastatin Calcium50%Rosuvastatin Calcium34%Pravastatin Sodium12%Simvastatin5%
    Part D<11 patients
    Beta blocker17.3%
    Carvedilol46%Metoprolol Succinate36%Metoprolol Tartrate18%
    Part D≥46 patients

    + 11 more classes in this area

  • Blood & clotting

    10.2%
    Factor Xa inhibitor7.4%
    Eliquis100%
    Part D≥37 patients
    P2Y12 inhibitor2.8%
    Clopidogrel100%
    Part D≥20 patients
  • Metabolism & gastrointestinal

    2%
    Potassium supplement1.1%
    Potassium Chloride100%
    Part D<11 patients
    SGLT2 inhibitor1%
    Farxiga100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”